Artesunate for Injection 120 mg
Formulation Overview: WHO first-line parenteral artemisinin-derivative sterile vial (120 mg artesunate with co-packed sodium bicarbonate activator & saline diluent) engineered for life-saving IV/IM emergency malaria treatment across endemic regions. Formulated with Artesunate 120 mg (120 mg) in Sterile Dry Powder Injection Vial + Co-packed Diluent dosage form under Antimalarials Medication, manufactured to IP / BP / USP Compendial standards and supplied in 1 Vial + Diluent USP Type I Glass Vial (with WFI & Bicarbonate Diluent) with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
| Item Code (SKU) | AKP-007-MAL |
| Catalog Reference | AKP-007 · SN 7 |
| Therapeutic Sector | Antimalarials Medication |
| Dosage Form | Sterile Dry Powder Injection Vial + Co-packed Diluent |
| Active Ingredient | Artesunate 120 mg |
| Strength / Purity | 120 mg |
| Clinical Indication | Severe and cerebral Plasmodium falciparum malaria requiring rapid parenteral parasitemia clearance |
| Specification Standard | IP / BP / USP Compendial |
| Packaging Format | 1 Vial + Diluent USP Type I Glass Vial (with WFI & Bicarbonate Diluent) |
| Shelf Life | 24–36 Months |
| Storage Conditions | Store below 25°C, protect from light & freezing; use immediately upon reconstitution |
| Minimum Order Quantity | 1000 Packs |
| Regulatory / Analytical Docs | Full eCTD / ACTD Modules 1–5 + Zone IVb Stability Available |
| African & Global NRA Readiness | NAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA |
| Stock Availability | In Stock · Immediate Commercial Dispatch |
| Supply Status | Commercial Export Ready |